ACP5 / Tartrate-resistant acid phosphatase type 5 · IHC design guide

Design Immunohistochemistry for ACP5

Plan chromogenic IHC-P for ACP5 using cytoplasmic staining in lung macrophages as a reference (HPA tissue IHC). The guide covers fixation consistency and interpretation of secreted, processed ACP5 forms (UniProt).

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for ACP5 (IHC for ACP5): expected localisation Cytoplasmic in lung macrophages (HPA tissue IHC), antibody A03277-1, validated IHC image, and IHC protocol steps — Printable **ACP5** IHC protocol sheet — expected localisation Cytoplasmic in lung macrophages (HPA tissue IHC), antibody A03277-1, controls and protocol steps. Open the full ACP5 IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

ACP5 Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	Cytoplasmic in lung macrophages (HPA tissue IHC)
	Staining pattern	Lung macrophages show cytoplasmic staining (HPA tissue IHC)
	Antigen retrieval	EDTA pH 8.0 HIER, heat-mediated (datasheet A03277-1)
	Positive control ⓘ	Lung
	Negative control ⓘ	Adipose tissue+4 more · see all

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A03277-1)
	Caveat	Secreted ACP5 may complicate cell-specific scoring (UniProt)
	Regulation	Expression regulation not annotated (UniProt)
	Isoform / epitope	5a is uncleaved; 5b is cleaved. Check epitope coverage (UniProt)

Section 1

Recommended ACP5 IHC & IF Protocols

The catalog antibody’s IHC-P protocol (datasheet A03277-1) is accompanied by published ACP5 IHC protocols from two articles (PMC7066063; PMC12639494).

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	Paraffin-embedded human spleen tissue; fixative not specified (datasheet A03277-1)
Fixation	Image fixative and duration unreported (datasheet A03277-1); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat retrieval: EDTA pH 8.0 (datasheet A03277-1); 20 min, 95–100 °C (standard)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% goat serum (datasheet A03277-1)
Primary antibody	Rabbit anti-ACP5, 2-5 μg/ml (datasheet A03277-1)
Primary incubation	Overnight at 4 °C (datasheet A03277-1)
Detection	Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A03277-1)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	ACP5-positive staining in macrophages of lung (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression in macrophages in lung. No signal in the no-primary control.

💡Decision noteStart with heat-mediated EDTA retrieval at pH 8.0 (datasheet A03277-1); the mouse maxilla study used a universal enhanced retrieval solution (PMC12639494).

Section 2

What Is the Expected ACP5 Staining Pattern?

ACP5 should produce cytoplasmic staining in lung macrophages, where HPA reports high expression (HPA: lung macrophages, High). HPA rates the tissue IHC pattern Enhanced but reports low consistency between antibody staining and RNA expression (HPA: tissue IHC). UniProt places ACP5 in lysosomes and in a secreted pool; it has no transmembrane segment (UniProt P13686: location and topology). Interpret staining by cell type and compartment together.

What am I looking at on my slide?
Strong cytoplasmic chromogen in lung macrophages, with comparatively clear surrounding tissue (HPA: lung macrophages, High).	This matches the reported IHC pattern (HPA: cytoplasmic expression in lung macrophages). Score the macrophages rather than the whole section; their distribution can make an otherwise pale field look heterogeneous (general IHC practice).
A chiefly nuclear, crisp membranous, or uniform extracellular signal replaces macrophage cytoplasmic staining.	Nuclear or membranous dominance conflicts with HPA’s cytoplasmic observation and UniProt’s lack of a transmembrane segment (HPA: tissue IHC; UniProt P13686: topology). Secreted ACP5 can complicate extracellular interpretation, so do not call that pattern specific on its own (UniProt P13686: location).
Strong staining occurs in bronchial respiratory epithelium or adipocytes instead of macrophages.	Those cell types were not detected in the supplied HPA IHC observations (HPA: bronchus respiratory epithelial cells; adipose adipocytes). Consider antibody cross-reactivity or detection-system signal, including endogenous peroxidase activity; check controls before assigning ACP5 expression (general IHC practice).
Broad, low-level chromogen covers many cells and the section background.	Diffuse color lacks the cell-restricted pattern reported for lung macrophages (HPA: tissue IHC). Review the no-primary control and detection chemistry, then adjust blocking, antibody concentration, washes, or chromogen development as indicated (general IHC practice).
No macrophage signal appears in a lung section with recognizable macrophages.	That conflicts with HPA’s high lung-macrophage observation (HPA: lung macrophages, High). Confirm that the macrophages are present, then check the antibody’s IHC-P instructions and reagent performance; an absent signal alone does not establish absent ACP5 (general IHC practice).

💡Expected ACP5 appearanceCall positive when lung macrophages show strong cytoplasmic staining (HPA: lung macrophages, High; HPA: cytoplasmic expression); dominant nuclear, epithelial, or field-wide color should prompt a specificity or background check (HPA: tissue IHC; general IHC practice).

How each factor affects the staining
Cell and compartment	HPA directly observes cytoplasmic ACP5 in lung macrophages (HPA: tissue IHC). UniProt also places ACP5 in lysosomes and a secreted pool (UniProt P13686: location); these annotations do not require a visually punctate IHC pattern.
Processing and secretion	Macrophages and dendritic cells secrete uncleaved 5a; osteoclasts secrete cleaved 5b (UniProt P13686: subcellular note). The supplied HPA IHC record does not distinguish these forms, so do not identify an isoform from chromogen distribution.
Evidence strength	HPA lists IHC as Enhanced for HPA057655 and HPA059463, while CAB002584 is Approved (HPA: antibody validation). Its tissue record is Enhanced yet notes low staining–RNA consistency (HPA: tissue IHC); preserve that caveat when interpreting weak or unexpected staining.
Negative cell comparators	HPA reports no detection in bronchial respiratory epithelium, adipocytes, and several other listed cell types (HPA: tissue IHC negatives). These are observed comparisons, not a guarantee that every specimen or detection run will be negative.
IF/ICC Q: should the fluorescence be lysosomal?	A: HPA summarizes ICC-IF as cytosol, marked uncertain, with images from A-431 and U-251MG (HPA: subcellular ICC-IF). UniProt annotates lysosomal and secreted ACP5 (UniProt P13686: location); fluorescence alone cannot settle the discrepancy.

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
Lung macrophages are unstained while tissue and counterstain are visible.	The expected positive population may be sparse, or the IHC detection run may have failed (HPA: lung macrophages, High; general IHC practice).	Locate macrophages morphologically, compare a known-positive lung section, and verify the catalog antibody’s IHC-P procedure and detection reagents (general IHC practice).
Macrophages and most neighboring cells stain equally.	The result loses the macrophage-enriched pattern observed by HPA; excess background or nonspecific binding is possible (HPA: tissue IHC; general IHC practice).	Inspect no-primary and appropriate negative controls. Optimize blocking, antibody concentration, washing, and chromogen time one variable at a time (general IHC practice).
Color persists in a no-primary control.	Primary-antibody-independent detection signal, including endogenous peroxidase activity in chromogenic IHC, is possible (general IHC practice).	Review the detection-system controls and apply its recommended endogenous-activity blocking step; reassess the control before scoring ACP5 (general IHC practice).
Strong nuclear or sharply membranous staining dominates.	That distribution conflicts with the reported cytoplasmic IHC pattern and lack of a transmembrane segment (HPA: tissue IHC; UniProt P13686: topology).	Check control slides and compare staining with a second independently validated IHC antibody where available (HPA: HPA057655 and HPA059463, IHC Enhanced; general IHC practice).
Bronchial respiratory epithelium stains prominently.	HPA recorded no detection in that cell population; cross-reactivity or detection background warrants investigation (HPA: bronchus respiratory epithelial cells; general IHC practice).	Compare macrophage staining in the same run, inspect controls, and verify the antibody’s IHC-P application before interpreting epithelial color as ACP5 (HPA: lung macrophages, High; general IHC practice).
Signal varies sharply between runs after retrieval changes.	Retrieval conditions can alter IHC signal generally; ACP5-specific fixation or retrieval sensitivity is unreported in the supplied HPA and UniProt records (general IHC practice; HPA and UniProt P13686: supplied records).	Return to the catalog antibody’s IHC-P instructions and compare retrieval conditions using the same known-positive and negative controls; do not infer an ACP5-specific fixation effect (general IHC practice).

Source: UniProt P13686 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing ACP5 staining

IHC analysis of Acid Phosphatase/ACP5 using anti-Acid Phosphatase/ACP5 antibody (A03277-1). Acid Phosphatase/ACP5 was detected in a paraffin-embedded section of human spleen tissue. Heat mediated antigen retrieval was performed in EDTA buffer (pH 8.0, epitope retrieval solution). The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 2 μg/ml rabbit anti-Acid Phosphatase/ACP5 Antibody (A03277-1) overnight at 4°C. Biotinylated goat anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using Strepavidin-Biotin-Complex (SABC) (Catalog # SA1022) with DAB as the chromogen.

A03277-1 · IHCIHC analysis of Acid Phosphatase/ACP5 using anti-Acid Phosphatase/ACP5 antibody (A03277-1). Acid Phosphatase/ACP5 was detected in a paraffin

IF analysis of Acid Phosphatase/ACP5 using anti-Acid Phosphatase/ACP5 antibody (A03277-1). Acid Phosphatase/ACP5 was detected in an immunocytochemical section of MCF-7 cells. Enzyme antigen retrieval was performed using IHC enzyme antigen retrieval reagent (AR0022) for 15 mins. The cells were blocked with 10% goat serum. And then incubated with 5 μg/mL rabbit anti-Acid Phosphatase/ACP5 Antibody (A03277-1) overnight at 4°C. DyLight®488 Conjugated Goat Anti-Rabbit IgG (BA1127) was used as secondary antibody at 1:100 dilution and incubated for 30 minutes at 37°C. The section was counterstained with DAPI. Visualize using a fluorescence microscope and filter sets appropriate for the label used.

A03277-1 · IFIF analysis of Acid Phosphatase/ACP5 using anti-Acid Phosphatase/ACP5 antibody (A03277-1). Acid Phosphatase/ACP5 was detected in an immunocy

A03277 · IFImmunofluorescence of TRAP in human liver tissue with TRAP antibody at 20 μg/mL.

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000102575-ACP5/tissue/cerebral+cortex#imid_17243707

HPA · LungHuman Protein Atlas IHC, Lung. Source: https://www.proteinatlas.org/ENSG00000102575-ACP5/tissue/lung#imid_17243586

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000102575-ACP5/tissue/colon#imid_17243625

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000102575-ACP5/tissue/liver#imid_17243626

HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody CAB002584; green = ACP5, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for ACP5 IHC & IF

🧪Run lung first and score macrophages for ACP5 staining (HPA: High in lung macrophages). Use adipose tissue as a negative comparator, scoring adipocytes, and expect adjacent non-macrophage cells on the lung slide to provide a background reference (HPA: Not detected in adipocytes; HPA: High in lung macrophages).

Positive control tissue: Lung (Macrophages, HPA High)

Negative control tissue: Adipose tissue (HPA Not detected)

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show ACP5 in A-431, U-251MG, with annotated localisation: Cytosol (uncertain) (HPA subcellular).

Technical controls: Include no-primary or secondary-only and host- and class-matched nonimmune rabbit antibody controls, plus an ACP5-knockout specimen as a biological negative if available (caption: rabbit primary and biotinylated goat anti-rabbit secondary; standard IHC controls). Block endogenous peroxidase and assess endogenous biotin before interpreting lung DAB staining with the biotin-based detection system (caption: SABC/DAB; standard IHC practice).

⚠️Feasibility: A target-specific fixation window and fixation effect are unreported, and the selected A03277-1 paraffin-section caption does not state the fixative (caption: fixative unreported). The demonstrated IHC workflow uses heat retrieval in EDTA at pH 8.0, followed by 2 μg/ml primary antibody overnight at 4°C; retrieval dependence beyond that example is unreported (caption: A03277-1 tissue IHC). The evidence does not establish whether frozen sections or IF are easier; for lung, assess macrophage pigment in chromogenic images and autofluorescence if using IF (HPA: High in lung macrophages; standard IHC/IF practice).

HPA tissue IHC evidence for ACP5

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Low consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Lung	Macrophages	High	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
Adipose tissue	Adipocytes	Not detected	Protein (IHC)	HPA →
Adrenal gland	Glandular cells	Not detected	Protein (IHC)	HPA →
Appendix	Glandular cells	Not detected	Protein (IHC)	HPA →
Bone marrow	Hematopoietic cells	Not detected	Protein (IHC)	HPA →
Breast	Adipocytes	Not detected	Protein (IHC)	HPA →

Section 3

Advanced ACP5 IHC Tips

Troubleshoot ACP5 staining in paraffin sections by checking retrieval, cell identity, cytoplasmic pattern, and controls before comparing signal across samples.

What should I change when ACP5 staining is weak after antigen retrieval?

Begin with heat-mediated retrieval in EDTA at pH 8.0 for paraffin sections (datasheet A03277-1). The selected tissue-IHC image used that condition before staining human spleen with 2 μg/ml primary antibody overnight at 4°C (caption A03277-1). If signal remains weak, compare a longer or shorter heating period on adjacent sections while keeping antibody concentration, detection, and exposure to DAB constant (standard IHC practice). Include a known positive section in each comparison, because a failed detection run can resemble incomplete retrieval (standard IHC practice). Record tissue damage alongside signal intensity so stronger staining is not mistaken for a better result (standard IHC practice).

Could fixation explain weak or patchy ACP5 staining?

Target-specific ACP5 sensitivity to fixation is unknown from the supplied evidence, and the selected paraffin-section caption does not state its fixative (caption A03277-1). Document the actual fixative and fixation time for each specimen before comparing staining between samples (standard IHC practice). Compare similarly processed positive and test sections using the same EDTA pH 8.0 retrieval and detection run, then assess both staining and tissue preservation (datasheet A03277-1; standard IHC practice). If a processing difference tracks with signal loss, report that association as a specimen-level observation rather than an established ACP5 fixation effect (standard IHC practice).

Where should convincing ACP5 staining appear in paraffin sections?

Assess cytoplasmic staining in the relevant cells: tissue IHC reports high expression in lung macrophages, while subcellular staining is described as cytosolic with uncertain localisation (HPA: High in lung macrophages; HPA: Cytosol, uncertain). ACP5 is also annotated as lysosomal and secreted, with no transmembrane segment, so a single crisp membrane rim is poorly supported as its expected pattern (UniProt P13686 localisation and topology). Examine cell morphology and distribution at matched magnification before calling a diffuse brown area positive (standard IHC practice). Compare with a negative reagent control and a positive section processed in the same run, especially when extracellular staining obscures cell boundaries (standard IHC practice).

Can this antibody distinguish ACP5 5a from 5b in tissue?

Do not assign staining to ACP5 5a or 5b unless the antibody epitope and processing sensitivity have been established separately (UniProt P13686 processing; supplied antibody caption). ACP5 can occur as an uncleaved monomer called 5a or a proteolytically processed, disulfide-linked two-chain form called 5b (UniProt P13686 subunit). The record associates secretion of 5a with macrophages and dendritic cells and secretion of 5b with osteoclasts, but cell context alone cannot prove which form this antibody detects (UniProt P13686 localisation; standard IHC interpretation). Score the observed cellular pattern as ACP5 immunoreactivity and state that form assignment remains unresolved (standard IHC practice).

How should I assess ACP5 in a separate multiplex IF experiment?

For a separate IF experiment, pair ACP5 with a validated marker of the expected cell type, such as a macrophage marker when assessing lung macrophages (HPA: High in lung macrophages; standard IF practice). Choose spectrally separated fluorophores and inspect an unstained section for tissue autofluorescence before interpreting apparent overlap; a far-red channel may help when shorter wavelengths are bright (standard IF practice). Because ACP5 is annotated as lysosomal and secreted without a transmembrane segment, plan permeabilisation for an intracellular epitope only after checking the antibody’s epitope information (UniProt P13686 topology and localisation; standard IF practice). The supplied paraffin IHC caption gives no IF fixation or permeabilisation condition for this antibody (caption A03277-1).

How can I reduce diffuse brown staining without losing ACP5 signal?

First compare a no-primary control with the stained section to locate signal arising from detection reagents or tissue rather than primary-antibody binding (standard IHC practice). The selected method used 10% goat serum, a biotinylated secondary, streptavidin–biotin detection, and DAB, so check serum blocking, secondary concentration, endogenous biotin, and peroxidase blocking within that workflow (caption A03277-1; standard IHC practice). Titrate the primary around its documented 2 μg/ml condition and keep DAB development consistent across controls and samples (caption A03277-1; standard IHC practice). ACP5 is an acid phosphatase, but its activity alone does not establish the source of brown DAB background (UniProt P13686 function; standard IHC practice).

How should I quantify ACP5 staining across tissue sections? ⚠ ANSWER MARKED FOR VERIFICATION

Define the cell population and tissue area before scoring, then measure the percentage of positive cells, an intensity-weighted H-score, or positive-cell density per mm² (standard IHC practice). For lung, score macrophages separately from other cells because high macrophage expression is the reported tissue-IHC pattern (HPA: High in lung macrophages). Normalise cell counts to the number of eligible cells or measured viable tissue area, and apply the same intensity thresholds and DAB development conditions to every section (standard IHC practice). Exclude folds, damaged edges, and necrotic areas using predefined rules, and report biological samples separately from multiple fields of one section (standard IHC practice).

When should apparent ACP5 positivity be treated as artefact?

Give greatest weight to staining in morphologically identified cells with a plausible cytoplasmic pattern, especially lung macrophages, rather than isolated nuclear or sharp membrane-only signal (HPA: High cytoplasmic staining in lung macrophages; UniProt P13686 topology). The selected spleen image supports staining in a paraffin section but does not identify its fixative or establish every positive cell type (caption A03277-1). Check whether positivity concentrates at tissue edges, folds, or necrotic zones, and whether it persists in a no-primary control (standard IHC practice). Distinguish antibody-based DAB staining from any separate enzyme-activity assay; endogenous ACP5 phosphatase activity alone does not identify the source of DAB signal (UniProt P13686 function; standard IHC practice).

Boster reagents

Best ACP5 / Tartrate-resistant acid phosphatase type 5 IHC Antibodies

The catalog pairs paraffin-section IHC images from human and mouse tissue with IF images from human tissue and cells (catalog image captions).

Real IHC data

Anti-Acid phosphatase/ACP5 Antibody ®

Cat # A03277-1

View product →

Real IF data Immunofluorescence of TRAP in human liver tissue with TRAP antibody at 20 μg/mL.

Anti-TRAP ACP5 Antibody

Cat # A03277

View product →

A03277-1 has IHC images of human spleen, lung and renal cancer tissue and mouse lung in paraffin sections, plus IF in MCF-7 cells (A03277-1 image captions). A03277 has IF data from human liver tissue at 20 μg/mL and no listed IHC application (A03277 image caption; catalog applications).

Which to pick: Choose A03277-1 for paraffin-section IHC: its human spleen image used EDTA retrieval at pH 8.0 and 2 μg/ml primary antibody; the fixative is unreported (A03277-1 IHC image caption). For tissue IF, choose A03277 based on its human liver image; for cellular IF/ICC, choose A03277-1 based on its MCF-7 image and listed ICC/IF applications (A03277 IF image caption; A03277-1 IF image caption and catalog applications). For work spanning species, A03277-1 lists human, mouse and rat reactivity, while its IHC-P dilution guidance names human and mouse (A03277-1 catalog reactivity and dilution guidance).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry P13686 (PPA5_HUMAN, Tartrate-resistant acid phosphatase type 5).
Human Protein Atlas. ACP5 tissue IHC expression (reliability: Enhanced).
Human Protein Atlas. ACP5 subcellular location (ICC-IF): Localized to the cytosol..
Human Protein Atlas. ACP5 antibody validation summary (3 antibodies).
Extracellular vesicles derived from dental follicle stem cells regulate tooth eruption by inhibiting osteoclast differentiation. Frontiers in cell and developmental biology 2024 — PMC11744031.
ACP5-positive macrophages contribute to cerebral oedema and neuroinflammation after traumatic brain injury. Clinical and translational medicine 2026 — PMC13613102.
Tartrate-Resistant Acid Phosphatase 5/ACP5 Interacts with p53 to Control the Expression of SMAD3 in Lung Adenocarcinoma. Molecular therapy oncolytics 2020 — PMC7066063.
Ultra-small coordination dihydromyricetin nanodots attenuate alveolar bone resorption in periodontitis through inhibition of ITGB3-Driven osteoclast differentiation. Materials today. Bio 2025 — PMC12639494.
PubMed PMID:2909539 — UniProt-cited evidence.
PubMed PMID:2338077 — UniProt-cited evidence.
PubMed PMID:14702039 — UniProt-cited evidence.